<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130010</url>
  </required_header>
  <id_info>
    <org_study_id>B-1604/342-006</org_study_id>
    <nct_id>NCT03130010</nct_id>
  </id_info>
  <brief_title>The Effect of Nefopam on Catheter-related Bladder Discomfort</brief_title>
  <official_title>The Effect of Nefopam on Catheter-related Bladder Discomfort: A Double-blind, Randomized, Controlled, Parallel Design Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study, the investigators evaluated whether nefopam 20 mg reduce the
      catheter-related bladder discomfort in patients undergoing foley catheter insertion
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>catheter-related bladder discomfort</measure>
    <time_frame>postoperative 1 hour</time_frame>
    <description>assessment of catheter-related bladder discomfort using visual analogue scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Nefopam</condition>
  <condition>Catheter-related Bladder Discomfort</condition>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One hour before the end of the operation, the control group was received 20 ml of saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The Nefopam group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nefopam or saline</intervention_name>
    <description>One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.</description>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_label>The Nefopam group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients scheduled to insert the catheter a new foley catheter more than 14 Fr in the
             operation site,

          2. Adults 20 to 75years of age

          3. American Society of Anesthesiologists Physical Classification 1,2 patients

          4. Patients who pre-agreed to the study

          5. Male patient

        Exclusion Criteria:

          1. Neurogenic bladder

          2. Patients diagnosed with irritable bladder

          3. study drug sensitive or contraindicated

          4. Patients with central nervous system or neurological disorder (epilepsy, patients
             receiving MAO inhibitor)

          5. Patients with urethral and prostate disorders

          6. Patients with previous history of myocardial infarction

          7. Patients with closed angle glaucoma
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eunsu Choi, pf</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National Univ. Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National Univ. Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nefopam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

